Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 25;16(2):101-107.
doi: 10.3400/avd.oa.22-00126.

Safety of SARS-CoV-2 Vaccination in Patients with Vascular Malformations: Patient-Reported Adverse Vaccine Reactions

Affiliations

Safety of SARS-CoV-2 Vaccination in Patients with Vascular Malformations: Patient-Reported Adverse Vaccine Reactions

Makoto Shiraishi et al. Ann Vasc Dis. .

Abstract

Objectives: Concerns among susceptible individuals, especially those with vascular malformations, have been raised by reports of thromboembolism following the administration of the SARS-CoV-2 vaccination against coronavirus disease 2019 (COVID-19). This study's goal was to assess any negative side effects that patients with vascular malformations who received the SARS-CoV-2 vaccine reported after receiving it. Materials and Methods: Through the three patient groups for vascular malformations in Japan in November 2021, a questionnaire was distributed to patients with vascular malformations who were 12 years of age or older. Multiple regression analysis was used to find relevant variables. Results: A total of 128 patients responded, representing a response rate of 58.8%. Ninety-six participants (75.0%) had received at least one dose of SARS-CoV-2 vaccine. In total, 84 (87.5%) and 84 (89.4%) subjects experienced at least 1 general adverse response following dose 1 and dose 2, respectively. Adverse reactions related to vascular malformations were reported by 15 participants (16.0%) after the 1st dose and 17 (17.7%) after the 2nd dose. Notably, no case of thromboembolism following vaccination was reported. Conclusion: The rate of vaccine-related adverse reactions in patients with vascular malformations is not different from that reported in the general population. There is no report of life-threatening responses in the research population.

Keywords: COVID-19; adverse reactions; vaccination; vascular anomalies; vascular malformations.

PubMed Disclaimer

Conflict of interest statement

Disclosure StatementDeclaration of Conflicting Interests: The authors declared no conflicts of interest. No funding was received for conducting this research.

Figures

None
Fig. 1 Reported adverse reactions of each type of vascular malformations following SARS-CoV-2 vaccine.

Similar articles

References

    1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982; 69: 412-20. doi: 10.1097/00006534-198203000-00002. - PubMed
    1. Enjolras O. Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations. J Dermatol 1997; 24: 701-10. doi: 10.1111/j.1346-8138.1997.tb02522.x. - PubMed
    1. Mulligan PR, Prajapati HJ, Martin LG, et al. Vascular anomalies: classification, imaging characteristics and implications for interventional radiology treatment approaches. Br J Radiol 2014; 87: 20130392. doi: 10.1259/bjr.20130392. - PMC - PubMed
    1. Mazereeuw-Hautier J, Syed S, Leisner RI, et al. Extensive venous/lymphatic malformations causing life-threatening haematological complications. Br J Dermatol 2007; 157: 558-63. doi: 10.1111/j.1365-2133.2007.08003.x. - PubMed
    1. Ndzengue A, Rafal RB, Balmir S, et al. Klippel-Trenaunay syndrome: an often overlooked risk factor for venous thromboembolic disease. Int J Angiol 2012; 21: 233-6. doi: 10.1055/s-0032-1328969. - PMC - PubMed